Skip to main content
. 2017 Jun 13;31(4):357–367. doi: 10.1007/s40259-017-0232-7

Table 3.

Summary of adverse events during the study (safety populationa)

Adverse events CT-P10 (n = 102) RTX (n = 51)
Any adverse event 73 (71.6) 43 (84.3)
Infusion-related reaction 20 (19.6) 10 (19.6)
Infection 39 (38.2) 21 (41.2)
Malignancy 0 1 (2.0)
Study drug discontinuation due to adverse event 6 (5.9) 4 (7.8)
Any serious adverse event 14 (13.7) 7 (13.7)

Data are presented as n (%)

RTX innovator rituximab

aAll patients who received at least one (full or partial) dose of CT-P10 or RTX